ANCA-Associated Vasculitis

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies

Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator

(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis

Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Avacostar - (PASS)

Biocollection of Patients With ANCA Associated Vasculitis

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis

Pediatric ANCA Associated-vasculitis

MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS

Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis

Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)